Biotech
Atkis Oncology
Atkis Oncology raises $175M Series B at $800M valuation
$175M
Total Raised
Series B
Latest Round
2023
Founded
90+
Employees
Boston, MA
1 min read
Quick Facts
Valuation
$800M
Latest Round Size
$175M
Latest Round Date
September 2024
Atkis Oncology: Series B Funding Round
Atkis Oncology has successfully raised $175M in Series B funding, reaching a valuation of $800M.
Company Overview
Developing precision oncology therapeutics
Funding Details
The Series B round was led by RA Capital Management, with participation from RTW Investments.
Company Information
- Headquarters: Boston, MA
- Founded: 2023
- Employees: 90+
- Category: Biotech
Investment
Atkis Oncology plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital Management: Verified investor in Series B
- RTW Investments: Verified investor in Series B
Key Investors
RA Capital Management
Lead Investor
Verified investor in Series B
RTW Investments
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M